LncRNA AC010789.1 Promotes Colorectal Cancer Progression by Targeting MicroRNA-432-3p/ZEB1 Axis and the Wnt/β-Catenin Signaling Pathway. 2020

Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Accumulating literatures have indicated that long non-coding RNAs (lncRNAs) are crucial molecules in tumor progression in various human cancers, including colorectal cancer (CRC). However, the clinical significance and regulatory mechanism of a vast majority of lncRNAs in CRC remain to be determined. The current study aimed to explore the function and molecular mechanism of lncRNA AC010789.1 in CRC progression. AC010789.1 found to be overexpressed in CRC tissues and cells. High expression of AC010789.1 was associated with lymph node metastasis and poor prognosis. Moreover, AC010789.1 silencing inhibited proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in vitro as well as tumorigenesis and metastasis in vivo. Mechanistically, we demonstrated that repression of AC010789.1 promoted miR-432-3p expression, and miR-432-3p directly binds to ZEB1. We then proved the anti-tumor role of miR-432-3p in CRC, showing that the inhibitory effect of AC010789.1 knockdown on CRC cells was achieved by the upregulation of miR-432-3p but downregulation of ZEB1. We also established that silencing AC010789.1 suppressed the Wnt/β-catenin signaling pathway. However, this inhibitory effect was partially counteracted by inhibition of miR-432-3p. In summary, these results reveal that silencing AC010789.1 suppresses CRC progression via miR-432-3p-mediated ZEB1 downregulation and suppression of the Wnt/β-catenin signaling pathway, highlighting a potentially promising strategy for CRC treatment.

UI MeSH Term Description Entries

Related Publications

Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
October 2017, Oncotarget,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
November 2021, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
July 2024, Cellular signalling,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
March 2024, Medical oncology (Northwood, London, England),
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
May 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
January 2021, Bioscience reports,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
February 2020, Journal of cellular biochemistry,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
September 2019, International journal of oncology,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
January 2021, Oncology research,
Weili Duan, and Xue Kong, and Juan Li, and Peilong Li, and Yinghui Zhao, and Tong Liu, and Helen Barong Binang, and Yunshan Wang, and Lutao Du, and Chuanxin Wang
November 2020, Oncology research,
Copied contents to your clipboard!